Emergent BioSolutions was awarded a $628 million contract with the US government through the Biomedical Advanced Research and Development Authority to build COVID-19 vaccine manufacturing capacity. The task order requires Emergent to use its Baltimore Bayview facility, designed for rapid production of large quantities of treatments and vaccines during emergencies, for the production of COVID-19 vaccine candidates through 2021.
HHS contracts with Emergent for COVID-19 vaccine production
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.